All Stories

  1. Severe Pregnancy-Associated Acute Kidney Injury and Maternal Vulnerability
  2. Use of Prokinetic Agents in Adult ICU Patients: An International Inception Cohort Study ( PATIENCE )
  3. Pathophysiology of pregnancy-associated acute kidney injury
  4. Renin–angiotensin system inhibitors (RASi) are not nephrotoxic – they protect the kidneys and the heart
  5. Changes in renal perfusion with brainstem death – revisiting the hypothesis of sympathetically mediated organ hypoperfusion
  6. Top Ten Tips to Manage Patients after Acute Kidney Injury (AKI)
  7. The impact of social determinants of health on acute kidney injury
  8. Hemoadsorption Combined with Hemodialysis (HAHD): a Consensus Statement from an International Expert Panel
  9. Kidney health during critical illness or upon major surgery
  10. European Society of Intensive Care Medicine Clinical Practice Guideline on fluid therapy in adult critically ill patients: A path toward improved patient management
  11. The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup
  12. The global epidemiology of acute kidney injury: challenges and opportunities
  13. Update on acute kidney injury: some progresses and a long way to go
  14. Diagnosis, diagnostic approach and challenges in pregnancy-associated AKI – The ADQI 32 consensus meeting
  15. Selected Serious Adverse Events in a Cohort of Adult ICU Patients: Protocol for a Sub‐Study of the PATIENCE Cohort
  16. European Society of Intensive Care Medicine Clinical Practice Guideline on fluid therapy in adult critically ill patients: Part 3—fluid removal at de-escalation phase
  17. State of the art: Renal recovery after AKI - from basic science to clinical practice
  18. Renal tubular epithelial cells: A revived kidney biomarker?
  19. Correction: Understanding and mitigating medication errors associated with patient harm in adult intensive care units: a scoping review
  20. Sepsis criteria and kidney function: eliminating sex, age and economic status biases
  21. Understanding and mitigating medication errors associated with patient harm in adult intensive care units: a scoping review
  22. Persistent severe AKI is bad—where to go now?
  23. Systematic Review and Meta-Analysis of Machine Learning Models for Acute Kidney Injury Risk Classification
  24. The effects of urine alkalinization on kidney function in critically ill patients with COVID-19: a proof-of-concept randomized clinical trial
  25. Kidney expert consultation and the outcomes of in hospital acute kidney injury
  26. Expanding the role of PoCUS in tailoring diuretic strategies for congestion management in critical care: authors’ reply
  27. The impact of Intensive Care Strain on Patients’ Outcomes during COVID-19 - a UNITE COVID study
  28. Hemoadsorption in septic shock – PRO
  29. NephroCheck AKI risk scores (TIMP-2 and IGFBP7) in pregnancy
  30. The heart–kidney axis in cirrhosis: rethinking hepatorenal and cardiorenal syndromes—authors’ reply
  31. DEFENDER trial: dapagliflozin for critically ill patients with acute organ dysfunction—implications for clinicians
  32. Ethical considerations in research involving ICU patients who lack capacity: navigating the updated Helsinki Declaration
  33. Can we use artificial intelligence to better treat acute kidney injury?
  34. Perioperative fluid management: evidence-based consensus recommendations from the international multidisciplinary PeriOperative Quality Initiative
  35. Terlipressin use in hepatorenal syndrome—acute kidney injury in cirrhosis. Author’s reply
  36. Environmental sustainability in intensive care: the path forward. An ESICM Green Paper
  37. Biomarkers in acute kidney injury
  38. Does amino acid infusion improve kidney outcomes in patients at high risk for postsurgical AKI?
  39. Terlipressin use in HRS–AKI and respiratory failure. Author's reply
  40. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting
  41. Preferences for albumin use in adult intensive care unit patients with shock: An international survey
  42. The REPERFUSE study protocol: The effects of vasopressor therapy on renal perfusion in patients with septic shock—A mechanistically focused randomised control trial
  43. Adjudication of a primary trial outcome: Results of a calibration exercise and protocol for a large international trial
  44. Using diuretic therapy in the critically ill patient
  45. Hepatorenal syndrome in the intensive care unit
  46. The environmental impact of laboratory measurements in high-resource ICUs
  47. Hemoadsorption
  48. Acute kidney injury in patients with burns
  49. Designing acute kidney injury clinical trials
  50. Micronutrient use in critical care: Survey of clinical practice
  51. Raised FGF23 Correlates to Increased Mortality in Critical Illness, Independent of Vitamin D
  52. Diuretics and ultrafiltration in heart failure
  53. Acute kidney injury
  54. Paths to organ damage and risk factors in AKI
  55. Improving risk prediction model quality in the critically ill: data linkage study
  56. Management of oliguria
  57. Indications for and Timing of Initiation of KRT
  58. Onco-nephrology: what the intensivist needs to know
  59. On myths about albumin and misconceptions that cause confusion: authors’ reply to “What’s wrong with the ten myths about albumin: three layers for an indisputable dispute”
  60. Ten myths about Albumin: don’t forget the endothelium. Author’s reply
  61. Erratum: Heparin versus citrate anticoagulation for continuous renal replacement therapy in intensive care: the RRAM observational study
  62. Effects of regional citrate anticoagulation on thrombin generation, fibrinolysis and platelet function in critically ill patients receiving continuous renal replacement therapy for acute kidney injury: a prospective study
  63. Extracorporeal Blood Purification Is Appropriate in Critically Ill Patients with COVID-19 and Multiorgan Failure: COMMENTARY
  64. Correction: Ten myths about albumin
  65. Ten myths about albumin
  66. Heparin versus citrate anticoagulation for continuous renal replacement therapy in intensive care: the RRAM observational study
  67. Dapagliflozin in patients with COVID-19: mind the kidneys
  68. Angiotensin II infusion in COVID‐19: An international, multicenter, registry‐based study
  69. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  70. Extracorporeal Treatment for Gabapentin and Pregabalin Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup
  71. The AKI care bundle: all bundle components are created equal—are they?
  72. Current practice and evolving concepts in septic shock resuscitation
  73. Renal replacement therapy in extra-corporeal membrane oxygenation patients: A survey of practices and new insights for future studies
  74. Do ventilatory parameters influence outcome in patients with severe acute respiratory infection? Secondary analysis of an international, multicentre14-day inception cohort study
  75. Cardiac Surgery Associated AKI Prevention Strategies and Medical Treatment for CSA-AKI
  76. The impact of viral mutations on recognition by SARS-CoV-2 specific T cells
  77. Executive Summary: Surviving Sepsis Campaign: International Guidelines for the Management of Sepsis and Septic Shock 2021
  78. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021
  79. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
  80. Vitamin D insufficiency in COVID-19 and influenza A, and critical illness survivors: a cross-sectional study
  81. Vascular access support teams: A multi-disciplinary response to optimise patient care during the COVID-19 pandemic
  82. Acute kidney injury in patients treated with immune checkpoint inhibitors
  83. Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning
  84. Definitions of acute renal dysfunction: an evolving clinical and biomarker paradigm
  85. Discharge Documentation and Follow-Up of Critically Ill Patients With Acute Kidney Injury Treated With Kidney Replacement Therapy: A Retrospective Cohort Study
  86. Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference
  87. Acute kidney injury in ECMO patients
  88. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
  89. Biomarker-Based Management of AKI: Fact or Fantasy?
  90. Acute kidney injury prevalence, progression and long-term outcomes in critically ill patients with COVID-19: a cohort study
  91. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
  92. Acute kidney injury in the critically ill: an updated review on pathophysiology and management
  93. Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study
  94. Relationship between the Clinical Frailty Scale and short-term mortality in patients ≥ 80 years old acutely admitted to the ICU: a prospective cohort study
  95. Nutrients and micronutrients at risk during renal replacement therapy: a scoping review
  96. Perioperative use of serum creatinine and postoperative acute kidney injury: a single-centre, observational retrospective study to explore physicians’ perception and practice
  97. Long-term kidney function of patients discharged from hospital after an intensive care admission: observational cohort study
  98. Postoperative acute kidney injury in adult non-cardiac surgery: joint consensus report of the Acute Disease Quality Initiative and PeriOperative Quality Initiative
  99. Prevention of Cardiac Surgery–Associated Acute Kidney Injury by Implementing the KDIGO Guidelines in High-Risk Patients Identified by Biomarkers: The PrevAKI-Multicenter Randomized Controlled Trial
  100. Restrictive fluid management versus usual care in acute kidney injury (REVERSE-AKI): a pilot randomized controlled feasibility trial
  101. Limiting Acute Kidney Injury Progression In Sepsis: Study Protocol and Trial Simulation*
  102. Nutritional assessment and support during continuous renal replacement therapy
  103. FGF23 ameliorates ischemia-reperfusion induced acute kidney injury via modulation of endothelial progenitor cells: targeting SDF-1/CXCR4 signaling
  104. Extracorporeal treatments for isoniazid poisoning: Systematic review and recommendations from the EXTRIP workgroup
  105. Wait and see for acute dialysis: but for how long?
  106. Predicting AKI: do we have the necessary tools?
  107. Early sedation with dexmedetomidine in ventilated critically ill patients and heterogeneity of treatment effect in the SPICE III randomised controlled trial
  108. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19
  109. Reduced exposure to vasopressors through permissive hypotension to reduce mortality in critically ill people aged 65 and over: the 65 RCT
  110. Association of plasma and urine NGAL with acute kidney injury after elective colorectal surgery: A cohort study
  111. Preventing infectious diseases in Intensive Care Unit by medical devices remote control: Lessons from COVID-19
  112. Surviving Sepsis Campaign: Guidelines on caring for critically ill COVID-19 patients
  113. Clearance of inflammatory cytokines in patients with septic acute kidney injury during renal replacement therapy using the EMiC2 filter (Clic-AKI study)
  114. Clearance of inflammatory cytokines in Patients with Septic Acute Kidney Injury During Renal Replacement Therapy Using the EMiC2 Filter (Clic-AKI study)
  115. Use of Biomarkers to Identify Acute Kidney Injury to Help Detect Sepsis in Patients With Infection
  116. In-House Production of Dialysis Solutions to Overcome Challenges During the Coronavirus Disease 2019 Pandemic
  117. What every Intensivist should know about COVID-19 associated acute kidney injury
  118. Net ultrafiltration prescription survey in Europe
  119. COVID-19-related organ dysfunction and management strategies on the intensive care unit: a narrative review
  120. Preferences for the measurement and supplementation of magnesium, phosphate and zinc in ICUs: The international WhyTrace survey
  121. Clearance of Inflammatory Cytokines in Patients with Septic Acute Kidney Injury During Renal Replacement Therapy Using the EMiC2 Filter (Clic-AKI Study)
  122. Neuromuscular blockade in patients with ARDS: a rapid practice guideline
  123. Clearance of micronutrients during continuous renal replacement therapy
  124. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup
  125. Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference
  126. Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup
  127. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
  128. Can Ventilatory Strategies in COVID-19 Have an Impact on Outcomes?<b> </b>
  129. Health-related quality of life in survivors of septic shock: 6-month follow-up from the ADRENAL trial
  130. Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury
  131. Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock
  132. Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study
  133. Parenteral thiamine for prevention and treatment of delirium in critically ill adults: a systematic review protocol
  134. Fluid removal associates with better outcomes in critically ill patients receiving continuous renal replacement therapy: a cohort study
  135. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference
  136. Roles of angiotensin II as vasopressor in vasodilatory shock
  137. Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation
  138. Acute kidney injury in critically ill cancer patients is associated with mortality: A retrospective analysis
  139. Sepsis at ICU admission does not decrease 30-day survival in very old patients: a post-hoc analysis of the VIP1 multinational cohort study
  140. Fluid management knowledge in hospital physicians: ‘Greenshoots’ of improvement but still a cause for concern
  141. Optimal management of acute kidney injury in critically ill patients with invasive fungal infections being treated with liposomal amphotericin B
  142. Renal replacement anticoagulant management: Protocol and analysis plan for an observational comparative effectiveness study of linked data sources
  143. A Multinational Observational Study Exploring Adherence With the Kidney Disease
  144. Pro: We Should Stop ACE Inhibitors Early Before Cardiac Surgery to Prevent Postoperative AKI
  145. Biomarker-guided implementation of the KDIGO guidelines to reduce the occurrence of acute kidney injury in patients after cardiac surgery (PrevAKI-multicentre): protocol for a multicentre, observational study followed by randomised controlled feasibili...
  146. The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study
  147. Protocol and statistical analysis plan for the REstricted fluid therapy VERsus Standard trEatment in Acute Kidney Injury—REVERSE‐AKI randomized controlled pilot trial
  148. Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study
  149. Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock
  150. Acute kidney injury as a risk factor of hyperactive delirium: A case control study
  151. Net Ultrafiltration Prescription and Practice Among Critically Ill Patients Receiving Renal Replacement Therapy
  152. Creatinine: From physiology to clinical application
  153. Micronutrients in critically ill patients with severe acute kidney injury – a prospective study
  154. A narrative review of the impact of surgery and anaesthesia on acute kidney injury
  155. Long‐term patient‐important outcomes after septic shock: A protocol for 1‐year follow‐up of the CLASSIC trial
  156. Lung–kidney interactions in critically ill patients: consensus report of the Acute Disease Quality Initiative (ADQI) 21 Workgroup
  157. Cumulative fluid accumulation is associated with the development of acute kidney injury and non-recovery of renal function: a retrospective analysis
  158. Report of the first AKI Round Table meeting: an initiative of the ESICM AKI Section
  159. How much centralization of critical care services in the era of telemedicine?
  160. Optimizing renal replacement therapy for patients who need extracorporeal membrane oxygenation: cross-talk between two organ support machines
  161. Effect of high-dose vitamin D3 on 28-day mortality in adult critically ill patients with severe vitamin D deficiency: a study protocol of a multicentre, placebo-controlled double-blind phase III RCT (the VITDALIZE study)
  162. Epidemiology of intra-abdominal infection and sepsis in critically ill patients: “AbSeS”, a multinational observational cohort study and ESICM Trials Group Project
  163. Acute Kidney Injury and Septic Shock—Defined by Updated Sepsis-3 Criteria in Critically Ill Patients
  164. Fluid Management in Acute Kidney Injury
  165. Vasopressor Therapy and Blood Pressure Management in the Setting of Acute Kidney Injury
  166. Less is more: ten reasons for considering to discontinue unproven interventions
  167. Renal replacement therapy for acute kidney injury in intensive care
  168. Conservative vs liberal fluid therapy in septic shock (CLASSIC) trial—Protocol and statistical analysis plan
  169. Evaluating Renal Stress Using Pharmacokinetic Urinary Biomarker Data in Critically Ill Patients Receiving Vancomycin and/or Piperacillin–Tazobactam: A Secondary Analysis of the Multicenter Sapphire Study
  170. Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial
  171. Changes in critically ill cancer patients’ short-term outcome over the last decades: results of systematic review with meta-analysis on individual data
  172. Quality Improvement Goals for Acute Kidney Injury
  173. Renal function after out-of-hospital cardiac arrest; the influence of temperature management and coronary angiography, a post hoc study of the target temperature management trial
  174. How to feed a patient with acute kidney injury
  175. Broad spectrum vasopressors: a new approach to the initial management of septic shock?
  176. Cumulative Prognostic Score Predicting Mortality in Patients Older Than 80 Years Admitted to the ICU
  177. Statement paper on diversity for the European Society of Intensive Care Medicine (ESICM)
  178. Distance between the tips of central venous catheters does not depend on same or opposite site access
  179. Diagnosis of death using neurological criteria in adult patients on extracorporeal membrane oxygenation: Development of UK guidance
  180. Challenges in the management of septic shock: a narrative review
  181. 10 myths about frusemide
  182. Ten tips to manage renal transplant recipients
  183. Serial Urinary Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 and the Prognosis for Acute Kidney Injury over the Course of Critical Illness
  184. STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: Study Protocol for a Multi-National, Multi-Center, Randomized Controlled Trial
  185. Continuous renal replacement therapy during extracorporeal membrane oxygenation
  186. Influence of neutropenia on mortality of critically ill cancer patients: results of a meta-analysis on individual data
  187. Risk prediction for acute kidney injury in acute medical admissions in the UK
  188. Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury
  189. Angiotensin in ECMO patients with refractory shock
  190. Unrecognised myocardial infarction and its relationship to outcome in critically ill patients with cardiovascular disease
  191. Correction to: Withholding or withdrawing of life-sustaining therapy in older adults (≥ 80 years) admitted to the intensive care unit
  192. suPAR as a marker of infection in acute kidney injury – a prospective observational study
  193. MAP of 65: target of the past?
  194. Cardiac and Vascular Surgery–Associated Acute Kidney Injury: The 20th International Consensus Conference of the ADQI (Acute Disease Quality Initiative) Group
  195. Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial
  196. Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II
  197. Withholding or withdrawing of life-sustaining therapy in older adults (≥ 80 years) admitted to the intensive care unit
  198. Exploring the impact of using measured or estimated values for height and weight on the relationship between BMI and acute hospital mortality
  199. Pragmatic studies for acute kidney injury: Consensus report of the Acute Disease Quality Initiative (ADQI) 19 Workgroup
  200. Angiotensin in Critical Care
  201. Erratum to “Intraoperative permissive oliguria – how much is too much?” [Br J Anaesth 119 (2017) 1075–1077]
  202. Kinetics of Urinary Cell Cycle Arrest Markers for Acute Kidney Injury Following Exposure to Potential Renal Insults
  203. Techniques and Modalities of Continuous Renal Replacement Therapy
  204. The Burden of Acute Kidney Injury and Related Financial Issues
  205. Drug management in acute kidney disease - Report of the Acute Disease Quality Initiative XVI meeting
  206. Intraoperative permissive oliguria – how much is too much?
  207. The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature
  208. Correction to: The Intensive Care Global Study on Severe Acute Respiratory Infection (IC-GLOSSARI): a multicenter, multinational, 14-day inception cohort study
  209. The effect of regional citrate anti-coagulation on the coagulation system in critically ill patients receiving continuous renal replacement therapy for acute kidney injury - an observational cohort study
  210. Characteristics and Outcome of Cancer Patients Admitted to the ICU in England, Wales, and Northern Ireland and National Trends Between 1997 and 2013*
  211. The impact of frailty on ICU and 30-day mortality and the level of care in very elderly patients (≥ 80 years)
  212. Pathophysiology of AKI
  213. Early troponin I in critical illness and its association with hospital mortality: a cohort study
  214. Angiotensin II for the Treatment of Vasodilatory Shock
  215. Elevated preoperative heart rate is associated with cardiopulmonary and autonomic impairment in high-risk surgical patients
  216. Renal Support for Acute Kidney Injury in the Developing World
  217. Vitamin D levels in critically ill patients with acute kidney injury: a protocol for a prospective cohort study (VID-AKI)
  218. Cardiac Troponin Release is Associated with Biomarkers of Inflammation and Ventricular Dilatation During Critical Illness
  219. Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017
  220. Low mean perfusion pressure is a risk factor for progression of acute kidney injury in critically ill patients – A retrospective analysis
  221. Renal recovery after acute kidney injury
  222. Diagnostic work-up and specific causes of acute kidney injury
  223. Have renal biomarkers failed in acute kidney injury? Yes
  224. Cardiac biomarkers are associated with maximum stage of acute kidney injury in critically ill patients: a prospective analysis
  225. The AKI glossary
  226. Current state of the art for renal replacement therapy in critically ill patients with acute kidney injury
  227. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup
  228. Predictions are difficult…especially about AKI
  229. The intensive care medicine agenda on acute kidney injury
  230. Lymphocyte Function in Human Acute Kidney Injury
  231. In critically ill patients with acute kidney injury stage 2, early initiation of renal replacement therapy is associated with reduced 90-day mortality compared to delayed initiation
  232. Intravascular versus surface cooling for targeted temperature management after out-of-hospital cardiac arrest – an analysis of the TTM trial data
  233. Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: practical applications
  234. Nomenclature for renal replacement therapy in acute kidney injury: basic principles
  235. Short-term and medium-term survival of critically ill patients with solid tumours admitted to the intensive care unit: a retrospective analysis
  236. Acute kidney injury 2016: diagnosis and diagnostic workup
  237. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock
  238. The two sides of creatinine: both as bad as each other?
  239. Goal-directed therapy and acute kidney injury: as good as it gets?
  240. The Dose Response Multicentre Investigation on Fluid Assessment (DoReMIFA) in critically ill patients
  241. Fatal cardiovascular instability secondary to hypercalcaemia and intracellular calcium deposition complicating T-cell leukaemia-lymphoma
  242. Diuretics in critical illness
  243. Anaemia is not a risk factor for progression of acute kidney injury: a retrospective analysis
  244. Incidence of tuberculosis is high in chronic kidney disease patients in South East England and drug resistance common
  245. Patient Selection and Timing of Continuous Renal Replacement Therapy
  246. Timing of Renal Replacement Therapy in Acute Kidney Injury
  247. Fluid overload and acute kidney injury: cause or consequence?
  248. Citrate anticoagulation for CRRT: don’t always trust the postfilter iCa results!
  249. Fenoldopam to prevent acute kidney injury after major surgery—a systematic review and meta-analysis
  250. Ionized calcium measurements during regional citrate anticoagulation in CRRT: we need better blood gas analyzers
  251. Increased Fluid Administration After Early Acute Kidney Injury is Associated with Less Renal Recovery
  252. Revised algorithm for heparin anticoagulation during continuous renal replacement therapy
  253. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients ...
  254. Fluid Composition and Clinical Effects
  255. Recognition and management of acute kidney injury in hospitalised patients can be partially improved with the use of a care bundle
  256. Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients
  257. AKI and haemodynamics
  258. Mood and illness experiences of adults with cystinosis
  259. Failure of Anticoagulant Thromboprophylaxis
  260. Timing of Renal Replacement Therapy
  261. Acute Kidney Injury Biomarkers
  262. Long-term sequelae from acute kidney injury: potential mechanisms for the observed poor renal outcomes
  263. Dose of Renal Replacement Therapy in AKI
  264. The definition of acute kidney injury and its use in practice
  265. Diagnosis of acute kidney injury
  266. Biomarkers for AKI improve clinical practice: no
  267. Novel risk factors for acute kidney injury
  268. Indications and management of mechanical fluid removal in critical illness
  269. Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study
  270. Nonleg Venous Thrombosis in Critically Ill Adults
  271. Prevention, detection and management of acute kidney injury: concise guideline
  272. DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current  -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
  273. Correction of Hyper- and Hyponatraemia during Continuous Renal Replacement Therapy
  274. Echocardiography Predicts Major Adverse Cardiovascular Events after Renal Transplantation
  275. Measuring biomarkers of acute kidney injury during renal replacement therapy: wisdom or folly?
  276. A prospective study of the impact of serial troponin measurements on the diagnosis of myocardial infarction and hospital and six-month mortality in patients admitted to ICU with non-cardiac diagnoses
  277. Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest
  278. Genome-Wide Sequencing of Cellular microRNAs Identifies a Combinatorial Expression Signature Diagnostic of Sepsis
  279. Restrictive Versus Liberal Transfusion Strategies for Older Mechanically Ventilated Critically Ill Patients
  280. Thrombocytopenia in Critically Ill Patients Receiving Thromboprophylaxis
  281. Heparin-Induced Thrombocytopenia in Medical Surgical Critical Illness
  282. Acute kidney injury: summary of NICE guidance
  283. Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis
  284. Acute kidney injury after cardiac surgery according to Risk/Injury/Failure/Loss/End-stage, Acute Kidney Injury Network, and Kidney Disease: Improving Global Outcomes classifications
  285. Predicting the development of acute kidney injury in liver cirrhosis - an analysis of glomerular filtration rate, proteinuria and kidney injury biomarkers
  286. RCPE UK Consensus Conference Statement: Management of acute kidney injury: the role
  287. Rates and determinants of informed consent: A case study of an international thromboprophylaxis trial
  288. Outcomes of Chronic Hemodialysis Patients in the Intensive Care Unit
  289. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury
  290. Improved Outcome of Severe Acute Pancreatitis in the Intensive Care Unit
  291. Retrospective analysis of outcome of women with breast or gynaecological cancer in the intensive care unit
  292. Beyond the Randomized Clinical Trial: Citrate for Continuous Renal Replacement Therapy in Clinical Practice
  293. Maintaining Normal Levels of Ionized Calcium during Citrate-Based Renal Replacement Therapy Is Associated with Stable Parathyroid Hormone Levels
  294. Letters to the editor
  295. Intravenous fluid use in the acutely unwell adult medical inpatient: improving practice through a clinical audit process
  296. Faculty of 1000 evaluation for Clinical factors associated with initiation of renal replacement therapy in critically ill patients with acute kidney injury-A prospective multicenter observational study.
  297. Successful management of severe hyponatraemia during continuous renal replacement therapy
  298. Renal replacement therapy in critically ill patients with acute kidney injury--when to start
  299. Care of the Critically Ill Emergency Department Patient with Acute Kidney Injury
  300. Clinical review: Biomarkers of acute kidney injury: where are we now?
  301. Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice
  302. Impact of different types of organ failure on outcome in intensive care unit patients with acute kidney injury
  303. Choice of Renal Replacement Therapy and Role of Haemodialysis in the Intensive Care Unit
  304. Role of Implantable Cardioverter Defibrillators for Dialysis Patients
  305. Challenges of defining acute kidney injury
  306. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease
  307. ICU and 6-month outcome of oncology patients in the intensive care unit
  308. Intensity of Continuous Renal-Replacement Therapy
  309. Management of sodium disorders during continuous haemofiltration
  310. Heparin algorithm for anticoagulation during continuous renal replacement therapy
  311. Effect of "collaborative requesting" on consent rate for organ donation: randomised controlled trial (ACRE trial)
  312. Response to ‘Could N-terminal pro-BNP be a useful marker for prediction of cardiac arrests in hemodialysis patients?’
  313. Correlation between parameters at initiation of renal replacement therapy and outcome in patients with acute kidney injury
  314. Cardiac arrests in hemodialysis patients: An ongoing challenge
  315. Acute Renal Failure in the Surgical Patient
  316. Renal failure in the intensive care unit: acute kidney injury compared to end-stage renal failure
  317. Correlation between the AKI classification and outcome
  318. Acute kidney injury on admission to the intensive care unit: where to go from here?
  319. The RIFLE criteria: Are the foundations robust?
  320. Frusemide Administration in Critically Ill Patients by Continuous Compared to Bolus Therapy
  321. Acute kidney injury in the intensive care unit according to RIFLE*
  322. Octreotide for relapsing sulfonylurea-induced hypoglycemia in a dialysis patient
  323. ACUTE RENAL FAILURE IN ICU - EVALUATION OF THE RIFLE CLASSIFICATION.
  324. Differential inducible nitric oxide synthase activity in circulating neutrophils vs. mononuclears of septic shock patients
  325. Prognosis of acute renal failure: an evaluation of proposed consensus criteria
  326. Pre-existing renal failure doubles 30-day mortality after heart transplantation
  327. Metabolic alkalosis in patients with renal failure
  328. Haemodialysis patients' views on their resuscitation status
  329. A 67‐year‐old kidney transplant patient with headache of uncertain origin
  330. Prophylaxis of cytomegalovirus infection in renal transplantation
  331. Coma mimicking brain death following baclofen overdose
  332. Acute renal failure following cardiopulmonary bypass: a changing picture
  333. Sedation in the Intensive Care Unit
  334. Lipid Profiles in Patients with Atherosclerotic Renal Artery Stenosis
  335. Effect of continuous haemofiltration on essential micronutrient levels
  336. Faculty of 1000 evaluation for Preoperative Statin Use and Postoperative Acute Kidney Injury.
  337. Faculty of 1000 evaluation for The fallacy of the BUN:creatinine ratio in critically ill patients.
  338. Faculty of 1000 evaluation for Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials.
  339. Faculty of 1000 evaluation for Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy.
  340. Faculty of 1000 evaluation for Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial.
  341. Faculty of 1000 evaluation for Sodium bicarbonate infusion to reduce cardiac surgery-associated acute kidney injury: a phase II multicenter double-blind randomized controlled trial.
  342. Faculty of 1000 evaluation for Prophylactic perioperative sodium bicarbonate to prevent acute kidney injury following open heart surgery: a multicenter double-blinded randomized controlled trial.
  343. Faculty of 1000 evaluation for Are Autopsy Findings Still Relevant to the Management of Critically Ill Patients in the Modern Era?
  344. Faculty of 1000 evaluation for Effect of the intensity of continuous renal replacement therapy in patients with sepsis and acute kidney injury: a single-center randomized clinical trial.